Vasogen Sees 2003 PMA For Vascular Disease Immune Modulation Therapy

Vasogen plans to submit a premarket approval application in 2003 for its immune modulation therapy (IMT) for peripheral arterial disease (PAD)

More from Archive

More from Medtech Insight